Dapagliflozin/sitagliptin

Last updated

Dapagliflozin/sitagliptin
Combination of
Dapagliflozin SGLT-2 inhibitor
Sitagliptin DPP-4 inhibitor
Clinical data
Trade names Sidapvia
Pregnancy
category
Routes of
administration 		By mouth
ATC code
Legal status
Legal status

Dapagliflozin/sitagliptin, sold under the brand name Sidapvia, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes. [1] It contains dapagliflozin, as propanediol monohydrate, a SGLT-2 inhibitor; and sitagliptin, as phosphate monohydrate, a DPP-4 inhibitor. [1] It is taken by mouth. [1]

References

  1. 1 2 3 4 5 "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 8 July 2024. Retrieved 8 July 2024.
  2. ↑ "Sidapvia (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 1 July 2024. Archived from the original on 7 July 2024. Retrieved 8 July 2024.
  3. ↑ "Sidapvia 10/100 dapagliflozin 10 mg (as propanediol monohydrate)/sitagliptin 100 mg (as phosphate monohydrate) film coated tablets blister pack (405540)". Therapeutic Goods Administration (TGA). 8 June 2024. Archived from the original on 8 July 2024. Retrieved 8 July 2024.
  4. ↑ Dunleavy K (24 July 2023). "AstraZeneca enlists SK Chemicals to produce diabetes combo drug Sidapvia". Fierce Pharma. Retrieved 8 July 2024.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.